GLP-1 medications produce significant weight loss. Up to 25–40% of that weight can come from lean mass, not just fat. The scale doesn't tell you which you're losing. DEXA scans, grip strength testing, and walking speed do. This is the measurement protocol that separates quality weight loss from weight loss that compromises your long-term health.
The muscle loss concern with GLP-1s is real but frequently misrepresented in both directions — overstated in some media coverage and dismissed by some clinicians. The evidence is nuanced and the implications differ substantially based on who you are.
| Trial | Drug | Total weight loss | Lean mass lost | % of loss from lean mass | Context |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg | ~15% | ~13% | 40–45% | Obese adults, minimal lifestyle support |
| SURMOUNT-1 | Tirzepatide 15mg | ~21% | ~11% | ~25% | Obese adults; tirzepatide's GIP activity may have mild anabolic signaling |
| BELIEVE (2025) | Semaglutide + bimagrumab | 22.1% | ~8% | ~8% (92% fat) | Anti-myostatin antibody combination — best body composition outcome in any GLP-1 trial to date |
| Bariatric surgery | — | ~25–30% | ~25–30% of loss | Similar to GLP-1s | Context: GLP-1s are not uniquely muscle-wasting vs other major interventions |
Lean mass figures from DXA substudies. STEP 1 lean mass data reflects the body-composition substudy population. BELIEVE trial published in JAMA 2025. Trial populations were primarily obese adults (BMI ≥30) — lean mass preservation is substantially better in active individuals with adequate protein intake.
DEXA (dual-energy X-ray absorptiometry) is the gold standard for body composition measurement. It directly measures lean mass, fat mass, and bone density in one scan. Smart scales using bioelectrical impedance have 3–8% error that is highly sensitive to hydration — they cannot reliably detect the 1–3 kg lean mass changes that matter on a GLP-1 protocol.
What to look for at 6 months: Your fat-to-lean-mass loss ratio. If you have lost 20 lbs and your DEXA shows 14 lbs fat + 6 lbs lean mass, that is 30% lean mass loss — at the lower end of the clinical range and manageable. If 10 lbs of a 20 lb loss is lean mass, that is 50% and warrants protocol adjustment.
Cost: $50–150 at university labs, sports medicine clinics, and body composition studios. Search "DEXA scan near me." Always use the same facility and machine for meaningful comparisons.
DEXA guide →Grip strength is a validated proxy for total body muscle quality and a sensitive early signal of accelerating lean mass loss. A calibrated hand dynamometer (~$30–50) gives you a reproducible monthly measurement that requires no facility visit.
Protocol: Dominant hand, seated, elbow at 90°, best of 3 trials with 1-minute rest between. Test at the same time of day (morning, before training).
Alarm signal: Grip strength declining more than 10% over 8 weeks. Per published GLP-1 monitoring guidance from Fitness Volt (2026): "If the time to walk 4 meters slows by more than 10% in eight weeks, the drug is taking more than the muscle-protective rules can replace."
Grip strength guide →Usual gait speed is a validated functional longevity marker that integrates cardiovascular capacity, muscle strength, balance, and neurological coordination. On a GLP-1, it is a particularly useful functional check because it captures neuromuscular performance without requiring gym equipment.
Protocol: Measure 4 meters on flat ground. Walk at your normal pace. Time from step 1 to step 4 (exclude acceleration and deceleration). Divide 4 by seconds = m/s. Target: above 1.0 m/s. Declining walking speed across monthly tests signals accelerating functional decline worth addressing.
Walking speed guide →The BELIEVE Phase 2b trial tested bimagrumab (an anti-myostatin antibody) combined with semaglutide. Published in JAMA in 2025, it showed 22.1% total weight loss with 92% of it being fat mass — the best body composition outcome ever seen in a GLP-1 trial. This combination is not yet clinically available, but it represents the direction the field is moving. Eli Lilly acquired Versanis Bio (which developed bimagrumab) for $1.93 billion specifically to advance this combination.
For now, the available tools — resistance training, adequate protein, creatine monohydrate, and DEXA monitoring — are the evidence-based approach. They do not produce bimagrumab-level fat-to-lean ratios, but consistently and meaningfully improve on unmanaged GLP-1 treatment.
Blood markers confirm organ safety and metabolic response. DEXA and grip strength confirm what you're actually losing. The Stack Analyzer connects both.